Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (241-250 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 TrialThomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Journal of the National Cancer Institute|July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant TrastuzumabFrancesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
European Journal of Heart Failure|December 21, 2010
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyThomas Eschenhagen, Thomas Force, Michael S Ewer, et al.
JACC. Cardiooncology|February 19, 2025
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology PrimerMarc P Bonaca, Ninian N Lang, Alice Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitorsEvert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
NPJ Precision Oncology|March 11, 2025
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancerPieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, et al.
European Journal of Heart Failure|December 7, 2023
European Society of Cardiology Core Curriculum for cardio-oncologyTeresa López-Fernández, Dimitrios Farmakis, Pietro Ameri, et al.
Pageof 26

Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2018
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 TrialThomas Ruhstaller, Anita Giobbie-Hurder, Marco Colleoni, et al.
Journal of the National Cancer Institute|July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant TrastuzumabFrancesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
European Journal of Heart Failure|December 21, 2010
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyThomas Eschenhagen, Thomas Force, Michael S Ewer, et al.
JACC. Cardiooncology|February 19, 2025
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology PrimerMarc P Bonaca, Ninian N Lang, Alice Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
The Lancet. Oncology|January 2, 2021
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolboxPeter Dubsky, Katja Pinker, Fatima Cardoso, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitorsEvert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, et al.
NPJ Precision Oncology|March 11, 2025
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancerPieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, et al.
European Journal of Heart Failure|December 7, 2023
European Society of Cardiology Core Curriculum for cardio-oncologyTeresa López-Fernández, Dimitrios Farmakis, Pietro Ameri, et al.
Pageof 26